Benzatropine mesilate

CLINICAL USE

Parkinson’s disease

Drug-induced extrapyramidal side effects

DOSE IN NORMAL RENAL FUNCTION

IV/IM (emergency use): 1–2 mg

PHARMACOKINETICS

Molecular weight :403.5

%Protein binding :95

%Excreted unchanged in urine : Majority (as unchanged drug and metabolites)

Volume of distribution (L/kg) :

half-life – normal/ESRD (hrs) :

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Start with low doses and adjust according to response

10 to 20 : Start with low doses and adjust according to response

<10 : Start with low doses and adjust according to response

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in GFR <10 mL/min

HD :Unknown dialysability. Dose as in GFR <10 mL/min

HDF/high flux :Unknown dialysability. Dose as in GFR <10 mL/min

CAV/VVHD :Unknown dialysability. Dose as in GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsPhenothiazines and tricyclic anti- depressants: may cause paralytic ileus which can be fatal

ADMINISTRATION

Reconstition

–

Route

IV, IM

Rate of Administration

–

Comments

–

OTHER INFORMATION

Benzatropine pharmacokinetics are not well studied, but the drug apparently is hepatically metabolised to conjugates and may undergo entero-hepatic recycling

Benzatropine has a cumulative effect and a prolonged duration of action; therefore, treatment should commence with the lowest possible dosage and be titrated according to response

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home